Table 1.
Demographic characteristics and co-morbidity of insulin group and glimepiride group in diabetic patients with background metformin therapy.
| Glimepiride (N = 1027) | Insulin (N = 1027) | ||
| n (%) | n (%) | P value | |
| Gender | .72∗ | ||
| Women | 462 (45) | 470 (45.8) | |
| Men | 565 (55) | 557 (54.2) | |
| Age, years | .011∗ | ||
| ≤40 | 37 (3.6) | 63 (6.1) | |
| 41–65 | 500 (48.7) | 457 (44.5) | |
| >65 | 490 (47.7) | 507 (49.4) | |
| Mean (SD) | 63.5 (12.5) | 64.2 (14.6) | .29† |
| Baseline comorbidity | |||
| Coronary artery disease | 431 (42) | 423 (41.2) | .72∗ |
| Stroke | 337 (32.8) | 311 (30.3) | .22∗ |
| Hypertension | 746 (72.6) | 752 (73.2) | .77∗ |
| Dyslipidemia | 654 (63.7) | 649 (63.2) | .82∗ |
| CCI scores | .24∗ | ||
| 0, 1 | 346 (33.7) | 381 (37.1) | |
| 2, 3 | 407 (39.6) | 378 (36.8) | |
| >3 | 274 (26.7) | 268 (26.1) | |
| DSCI scores | .59∗ | ||
| 0 | 703 (68.5) | 683 (66.5) | |
| 1 | 229 (22.3) | 238 (23.2) | |
| ≥2 | 95 (9.3) | 106 (10.3) | |
| DM drugs | |||
| TZDs | 117 (11.4) | 107 (10.4) | .48∗ |
| Alpha glucosidase inhibitors | 260 (25.3) | 239 (23.3) | .28∗ |
| DPP-4i | 208 (20.3) | 197 (19.2) | .54∗ |
| Mean DM duration, days (medium) | 1724 (1106) | 1630 (1152) | |